VS. COMPETITORS

SUPARTZ FX meets your patients’ needs

Since the introduction of SUPARTZ FX in 1987, more than 300 million injections have been prescribed globally. (19) The #1 choice worldwide (21), SUPARTZ FX has:

Proven effectiveness
SUPARTZ FX was found to be more effective than control in an integrated analysis of 5 prospective, randomized, double-blind, placebo-controlled and multicenter studies. (12,13)

Safety similar to saline placebo
In an integrated analysis of 5 clinical studies, adverse events occurred at similar rates in the patients treated with SUPARTZ FX and those treated with a saline placebo. (12,13)

Flexible dosing
Approved for 5 injections, but some patients may benefit from as few as 3 injections. The safety of repeat injections of SUPARTZ FX has been established. (13)

A high level of active ingredient
SUPARTZ FX delivers up to 125 mg of sodium hyaluronate per 5-injection series.

To find out how SUPARTZ FX can meet your patients’ unique needs, see the comparisons for SUPARTZ FX and SYNVISC, SUPARTZ FX and HYALGAN, SUPARTZ FX and EUFLEXXA, and SUPARTZ FX and ORTHOVISC.


SUPARTZ FX vs. SYNVISC®

vs_Synvisc


SUPARTZ FX vs. HYALGAN®

vs_Hyalgan


SUPARTZ FX vs. EUFLEXXA™

vs_Euflexxa


SUPARTZ FX vs. ORTHOVISC®

vs_Orthovisc


SUPARTZ FX vs. SYNVISC-ONE®

vs_Synvisc-One


SUPARTZ FX vs. MONOVISC®

vs_Monovisc


SUPARTZ FX vs. GEL-ONE®

vs_Gel-One

*All trademarks are the properties of their respective companies.

SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found here or by contacting customer service at
800-396-4325.